Herrera-García JC, Montiel CJS, Caballero-López CG, Arellano-Montellano EI, Jaramillo-Arellano LE, Espinosa AA

Language: Spanish
References: 11
Page: 692-696
PDF size: 352.17 Kb.

ABSTRACT

Objective: The prevalence of eosinophilia in chronic obstructive pulmonary disease is of great importance for the prevention of complications and to treat episodes of overactivity. The existence of a bio-marker would allow this monitoring. The review of the literature reveals the possible eosinophilia-chronic obstructive pulmonary disease relationship. There is little information in medical studies.
Material and Method: We designed a descriptive observational study of the population attended in the external consultation of Pneumology in the University Hospital of Puebla. The following variables were analyzed: age, sex, years of diagnosis of chronic obstructive pulmonary disease, blood count (diagnosis of eosinophilia with › 2% or more than 200 total cells), severity (by GOLD) and number of exacerbations in one year of study.
Results: Fifty patients with a diagnosis of chronic obstructive pulmonary disease (74% female and 26% male), 50% associated with smoking and 50% associated with wood smoke were present; 36% had representative eosinophilia (greater than 2% or greater than 200 total cells), 64% had non-representative eosinophilia (less than 2% or less than 200 total cells).
Conclusion: This work demonstrates in a population the importance of eosinophilia as a biomarker in the phenotype of chronic obstructive pulmonary disease that allows adequate treatment and aimed at improving quality of life and to decrease the progression and appearance of complications and exacerbations.

REFERENCES

1. Dave Singh, et al on behalf of the ECLIPSE investigators: Blood eosinophil measurements may be useful for selecting COPD patients for different therapeutic approaches. http:// ow.ly/BY19D. Oct 16 2014.

2. Grupo de Trabajo de GesEPOC. Guía de Práctica Clínica para el Diagnóstico y Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) - Guía Espanola de la EPOC (GesEPOC). Arch Bronconeumol 2012;48 Supl 1:2-58.

3. Hurst JR, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128- 38.

4. Postma DS, et al. The asthma-COPD overlap syndrome. N Engl J Med 2015;373:1241-9.

5. Soler-Cataluna JJ, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol 2012;48:331-7.

6. Singh D, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J 2014;44:1697-700.

7. Christenson SA, et al. Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;191:758-66.

8. Pascoe S, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: A secondary analysis of date fromtwo parallel randomised controlled trials. Lancet Respir Med 2015;3:435-42.

9. Siddiqui SH, et al. Blood eosinophils: A biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;192:523-5.

10. Marks-Konczalik J, et al. A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with ≤ 2% and > 2% blood eosinophils. Respir Med 2015;109:860-9.

11. Siva R, et al. airway inflammation and exacerbations of COPD: A randomised controlled trial. Eur Respir J 2007;29:906-13.